-
Weigao Pharmaceutical Co., Ltd. and Taiwan Baoling Fujin Biotechnology Co., Ltd. to develop new kidney drug nephoxil in mainland China
Time of Update: 2015-02-04
Recently, Shandong Weigao Pharmaceutical Co., Ltd and Taiwan Baoling Fujin Biotechnology Co., Ltd signed a letter of intent for cooperation in Taipei city to form a joint venture The two sides will ta
-
Kaibao Pharmaceutical Co., Ltd. invested 95 million yuan to develop a new antidepressant drug, youxinding capsule, in cooperation with Shanghai Traditional Chinese medicine innovation and research center
Time of Update: 2015-02-04
On January 26, 2015, Shanghai Traditional Chinese Medicine Innovation Research Center (hereinafter referred to as "the center") and Shanghai Kaibao Pharmaceutical Co., Ltd (hereinafter referred to as
-
Enoxaparin sodium of Shuanglu Pharmaceutical Co., Ltd. is expected to obtain production approval in June
Time of Update: 2015-02-04
According to the information of the State Food and Drug Administration (CFDA), enoxaparin sodium and its preparations declared by Shuanglu Pharmaceutical (002038 SZ) have entered the stage of waiting
-
Transfer of the first five new traditional Chinese medicine in Xinjiang to Xinjiang Uygur pharmaceutical industry under humanwell pharmaceutical
Time of Update: 2015-02-03
Zhang Xiaolei, director of science and Technology Department of Xinjiang Uygur Autonomous Region and President of Xinjiang branch, delivered a speech at the signing ceremony of Xinjiang Institute of p
-
Baiyunshan and Zhongnanshan research on isatis root, which is expected to be developed into a new antiviral drug
Time of Update: 2015-02-03
After the closing of the market on February 2, Baiyunshan's Li Jiacheng joint venture Baiyunshan and Huang announced in the First Affiliated Hospital of Guangzhou Medical University where Zhong Nansha
-
Tianjin International Biomedical Joint Research Institute entered the "national team" of national major new drug creation
Time of Update: 2015-02-03
According to Tianjin International Biomedical Joint Research Institute, focusing on the major strategic needs of the country, the Institute has made a number of breakthrough achievements by focusing o
-
CFDA becomes the "defendant" again because it does not approve the clinical trial
Time of Update: 2015-02-01
Guangzhou bercello Pharmaceutical Co., Ltd., a pharmaceutical company that filed a lawsuit with the State Food and Drug Administration for failing to obtain approval for clinical trials of new drugs,
-
Approval of polyprizin granules opens the new drug prelude of hispec this year
Time of Update: 2015-01-29
Polyprizin is a product of general medicine upgrading Its indication is mainly gastric ulcer It is a protective agent of gastric mucosa with multiple mechanisms The second company has obtained the app
-
Hualan biology is the first to obtain the approval for clinical trial of h7n9 influenza vaccine
Time of Update: 2015-01-29
The national pharmaceutical regulatory authorities are speeding up the approval of class 1 innovative drugs Only yesterday, the two heavyweight biological vaccine drugs obtained clinical approval, clo
-
Haizheng 1.1 new drug dtrmhs-07 is qualified for CDE special approval
Time of Update: 2015-01-28
Although dtrmhs-07, a new drug of category 1.1 declared by Zhejiang Haizheng at the end of last year, failed to catch up with the last bus of 2014, it made a good start in the new year CDE undertook t
-
GSK two melanoma drugs approved in China
Time of Update: 2015-01-28
GlaxoSmithKline's Lama single drug was approved for clinical use last week, and it continued to work this week Two drugs for melanoma were approved for clinical use by CFDA The trametinib tablets and
-
The first domestic new anti-T-cell lymphoma drug "xidaban" released by microchip biology
Time of Update: 2015-01-28
On the morning of January 27, Shenzhen released the first domestic new anti-T-cell lymphoma drug - "original new drug, National 863 and special achievement of major new drug creation xidaban amine" de
-
CDE drug review weekly report (2015.1.19-1.25)
Time of Update: 2015-01-26
1 Of the 40 drugs under examination and approval, there are 32 chemicals, 7 biological products for treatment and 1 biological product for prevention No Chinese medicine has entered the examination an
-
Check the approved drug approval number in the last 8 days of 2014
Time of Update: 2015-01-24
As of January 22, 2015, according to the tracking of national CFDA approval documents by Xianda data 3.0, in the last eight days of December 2014, CFDA approved a total of 52 drug approval documents,
-
"Turning point" of new drug application in Shandong Province
Time of Update: 2015-01-24
Recently, it was learned from the food and Drug Administration of Shandong Province that in 2014, there were 399 new drug applications accepted and examined in Shandong Province, an increase of 122 ov
-
East China Sea pharmaceutical micro ecological new drug industrialization technology won the first prize of scientific and technological progress in Shandong Province
Time of Update: 2015-01-23
On the morning of January 22, 2015, the Shandong science and technology award conference was successfully concluded, and all awards were announced Qingdao Donghai Pharmaceutical Co., Ltd won the first
-
Wang Xijuan, chairman of Kangchen Pharmaceutical Co., Ltd.: a female leader who adheres to the research and development of innovative drugs
Time of Update: 2015-01-22
Picture: Wang Xijuan, chairman of Kangchen pharmaceutical, in the winter of Beijing, if there is no strong wind, no haze, the sun pours into the whole city, beautiful and luxurious On the day of inter
-
Taiantang pharmaceutical snake fat shenhuang ointment obtained new drug certificate and production approval
Time of Update: 2015-01-22
Guangdong taiantang Pharmaceutical Co., Ltd announced in the afternoon of January 22 that recently, the company received the new drug certificate and drug registration approval document of "snake fat
-
Highlights of new drugs approved in China in 2013 / 2014
Time of Update: 2015-01-22
At the end of the year, all major enterprises are busy with a year's work summary For pharmaceutical enterprises, business income, operating cost, net profit and other vital data inventory are natural
-
Research and development of antitumor immune drugs with low profile layout in Baiji Shenzhou
Time of Update: 2015-01-21
After completing the clinical research stage, the first round of financing and the milestone payment of Merck xuelano for three candidate drugs, Baiji Shenzhou has focused on the possibility of immuno
